US FDA approves UCB's Bimzelx to treat adults with moderate to severe plaque psoriasis

Media coverage

• Title	US FDA approves UCB's Bimzelx to treat adults with moderate to severe plaque psoriasis
  Media name/outlet	PharmaBiz
  Country/Territory	India
  Date	19/10/23
  Persons	Mark Lebwohl

• Title	-UCB - BIMZELX Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis
  Media name/outlet	M2 PressWIRE
  Country/Territory	United States
  Date	19/10/23
  Persons	Mark Lebwohl

• Title	-UCB - BIMZELX Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis
  Media name/outlet	ENP Newswire
  Country/Territory	United Kingdom
  Date	19/10/23
  Persons	Mark Lebwohl